| Execution period | 5 years |
|---|
NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,049.00
- Market cap
- ₹50,312 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 44.6×Sector 46.1×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Gland Pharma Other Announcement
Gland Pharma Limited has filed the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Gland Pharma Annual General Meeting
Gland Pharma issued a postal ballot notice to seek shareholder approval for appointing Mr. Xingli Wang as Non-Executive Director. E-voting runs October 7 to November 5, 2026.
Gland Pharma Management Change
Gland Pharma Limited announced the resignation of director Wenjie Zhang and the appointment of Xingli Wang as a Non-Executive Non-Independent Director effective October 1, 2026.
Gland Pharma Acquisition Worth ₹199.5 Cr
Gland Pharma Limited's board approved a USD 21 million investment in its subsidiary, Gland USA, to acquire a 60% stake in Novelstar Pharma Inc. This acquisition facilitates business expansion in the USA.
- Value
- ₹199.5 Cr
- Execution
- By October 31, 2026
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.